MyBiotics Pharma, a microbiome therapeutics company based in Israel, announced that it has received an investment from Mii Fund, a partnership with Maruho Co Ltd, Japan's preeminent leader in dermatology.

MyBiotics will use the funds to advance its microbiome therapeutics pipeline and continue to enhance its unique microbiome platform technologies. In addition, the company is initiating a development programme in the field of skin microbiome, leveraging the support of the Mii Fund & Lab, and the relationship with Maruho Co Ltd.

MyBiotics has developed breakthrough, scalable and robust culturing, fermentation, and delivery technologies for generating a highly stable and diverse bacterial community that can be used to restore microbiome equilibrium. These technologies are effective for single microbes, complex microbial consortia and whole microbiome products, and are integrated with a computational AI platform. 

"Together with Maruho we are excited about the potential of microbiome-based therapeutics in dermatology and skin care. With the combination of its microbiome productisation and delivery platforms and AI capabilities, MyBiotics is perfectly positioned to bring a new category of solutions to unmet needs this space," said Eran Perry, Managing Director, Mii Fund.

"The transaction will allow us to strengthen our technology platforms and accelerate the development of our microbiome-based pipeline towards a more significant fund raising planned later this year," stated David Daboush, Co-Founder and CEO, MyBiotics Pharma.

"We are extremely pleased to collaborate with Mii Fund and Maruho, which dominates Japan's dermatology market. This also marks our entrance into the field of dermatology, where we will leverage our technologies to develop novel skin products.”